logo

CLRB

Cellectar·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

CLRB fundamentals

Cellectar (CLRB) released its earnings on Nov 13, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -1.41 (YoY -252.50%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-1.41
-252.50%
Report date
Nov 13, 2025
CLRB Earnings Call Summary for Q3,2025
  • EMA Regulatory Win: Iopofosine eligible for EU conditional approval with 80% historical success rate.
  • Phase III Trial Costs: $15M to initiate U.S. confirmatory study; full enrollment ~$28M.
  • Pipeline Progress: CLR 125 TNBC trial dosing imminent; CLR 225 pancreatic cancer trial pending funding.
  • Financial Runway: $12.6M cash + $5M post-Q3 raise, funding through Q3 2026.
  • Strategic Partnerships: Actinium-225 supply secured; global partner discussions active.
EPS
Revenue

Revenue & Expenses

Key Indicators

Cellectar (CLRB) key financial stats and ratios, covering profitability, financial health, and leverage.
Cellectar (CLRB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Cellectar (CLRB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Cellectar (CLRB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Cellectar (CLRB) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Cellectar (CLRB) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield